BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 19582880)

  • 21. The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
    Salmi S; Siiskonen H; Sironen R; Tyynelä-Korhonen K; Hirschovits-Gerz B; Valkonen M; Auvinen P; Pasonen-Seppänen S
    Melanoma Res; 2019 Jun; 29(3):237-247. PubMed ID: 30399061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. M2-macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer.
    Aljabery F; Olsson H; Gimm O; Jahnson S; Shabo I
    Urol Oncol; 2018 Apr; 36(4):159.e19-159.e26. PubMed ID: 29288002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of M2-macrophages in uveal melanoma and relation with survival.
    Bronkhorst IH; Ly LV; Jordanova ES; Vrolijk J; Versluis M; Luyten GP; Jager MJ
    Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):643-50. PubMed ID: 20811059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High intratumoral macrophage content is an adverse prognostic feature in anaplastic large cell lymphoma.
    Pedersen MB; Danielsen AV; Hamilton-Dutoit SJ; Bendix K; Nørgaard P; Møller MB; Steiniche T; d'Amore F
    Histopathology; 2014 Oct; 65(4):490-500. PubMed ID: 24592992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective approach for upper rectal cancer treatment: total mesorectal excision and preoperative chemoradiation are seldom necessary.
    Marinello FG; Frasson M; Baguena G; Flor-Lorente B; Cervantes A; Roselló S; Espí A; García-Granero E
    Dis Colon Rectum; 2015 Jun; 58(6):556-65. PubMed ID: 25944427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of macrophage infiltration in leiomyosarcomas.
    Lee CH; Espinosa I; Vrijaldenhoven S; Subramanian S; Montgomery KD; Zhu S; Marinelli RJ; Peterse JL; Poulin N; Nielsen TO; West RB; Gilks CB; van de Rijn M
    Clin Cancer Res; 2008 Mar; 14(5):1423-30. PubMed ID: 18316565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer-associated fibroblasts and CD163-positive macrophages in oral squamous cell carcinoma: their clinicopathological and prognostic significance.
    Fujii N; Shomori K; Shiomi T; Nakabayashi M; Takeda C; Ryoke K; Ito H
    J Oral Pathol Med; 2012 Jul; 41(6):444-51. PubMed ID: 22296275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Ratio of CD86+/CD163+ Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer.
    Xu G; Jiang L; Ye C; Qin G; Luo Z; Mo Y; Chen J
    Front Immunol; 2021; 12():724429. PubMed ID: 34512652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of macrophage antigens by tumor cells.
    Shabo I; Svanvik J
    Adv Exp Med Biol; 2011; 714():141-50. PubMed ID: 21506012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial.
    Tan KL; Scott DW; Hong F; Kahl BS; Fisher RI; Bartlett NL; Advani RH; Buckstein R; Rimsza LM; Connors JM; Steidl C; Gordon LI; Horning SJ; Gascoyne RD
    Blood; 2012 Oct; 120(16):3280-7. PubMed ID: 22948049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD163 immunohistochemistry is superior to CD68 in predicting outcome in classical Hodgkin lymphoma.
    Klein JL; Nguyen TT; Bien-Willner GA; Chen L; Foyil KV; Bartlett NL; Duncavage EJ; Hassan A; Frater JL; Kreisel F
    Am J Clin Pathol; 2014 Mar; 141(3):381-7. PubMed ID: 24515766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
    Tsutsumi S; Tabe Y; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Shioya M; Saito J; Asao T; Nakano T; Kuwano H
    Anticancer Res; 2011 Nov; 31(11):3963-7. PubMed ID: 22110227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of the infiltration of CD163
    Huang X; Pan Y; Ma J; Kang Z; Xu X; Zhu Y; Chen J; Zhang W; Chang W; Zhu J
    Cancer Med; 2018 May; 7(5):1731-1741. PubMed ID: 29573574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD163
    Omilian AR; Cannioto R; Mendicino L; Stein L; Bshara W; Qin B; Bandera EV; Zeinomar N; Abrams SI; Hong CC; Yao S; Khoury T; Ambrosone CB
    Breast Cancer Res; 2024 May; 26(1):75. PubMed ID: 38720366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
    Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclooxygenase 2 expression in rectal cancer is of prognostic significance in patients receiving preoperative radiotherapy.
    de Heer P; Gosens MJ; de Bruin EC; Dekker-Ensink NG; Putter H; Marijnen CA; van den Brule AJ; van Krieken JH; Rutten HJ; Kuppen PJ; van de Velde CJ;
    Clin Cancer Res; 2007 May; 13(10):2955-60. PubMed ID: 17504996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate.
    Folkesson J; Birgisson H; Pahlman L; Cedermark B; Glimelius B; Gunnarsson U
    J Clin Oncol; 2005 Aug; 23(24):5644-50. PubMed ID: 16110023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
    Kato T; Fujii T; Ide M; Takada T; Sutoh T; Morita H; Yajima R; Yamaguchi S; Tsutsumi S; Asao T; Oyama T; Kuwano H
    Anticancer Res; 2014 Jun; 34(6):3141-6. PubMed ID: 24922685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
    Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
    Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.